XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
S
S

Sanofi

News

Reuters - 2 days ago

Bpifrance eyes investment in Sanofi's consumer health business

Bpifrance eyes investment in Sanofi's consumer health business July 4 (Reuters) - Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's SASY.PA consumer health unit, Bloomberg News reported on Thursday. The French public investment bank is in talks with "many funds" and may team up with the winning bidder for Sanofi's consumer health unit, Gonzalo was quoted as saying.
S
Reuters - 4 days ago

EU approves Sanofi's Dupixent for 'smoker's lungs'

EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi SASY.PA and partner Regeneron REGN.O on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States. The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a re
R
S
Reuters - 5 days ago

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S
Reuters - 5 days ago

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge By Brendan Pierson July 1 (Reuters) - A Delaware judge rebuffed a request by GSK GSK.L and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward. The ruling by Judge Vivian Medinilla of the Delaware Superior Court means that the drugmakers, which also include Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, will have to ask the Delaware Su
G
P
S
Reuters - 5 days ago

Sanofi eyes German insulin investment of up to $1.6 bln, source says

UPDATE 2-Sanofi eyes German insulin investment of up to $1.6 bln, source says Adds context on French politics in fourth paragraph, details on Novo Nordisk in paragraphs 8 and 9 BERLIN, July 1 (Reuters) - French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.
S
Reuters - 6 days ago

Sanofi eyes German insulin investment of up to $1.6 bln, source says

Sanofi eyes German insulin investment of up to $1.6 bln, source says BERLIN, July 1 (Reuters) - French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major site in Frankfurt, Germany, to upgrade the production of long-acting insulin shots, a person familiar with the plan told Reuters on Monday.
S
Reuters - 6 days ago

Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says

UPDATE 1-Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says Adds comments by government, company in paragraphs 3 and 4 FRANKFURT, July 1 (Reuters) - French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
S
Reuters - 6 days ago

Scientists wary of bird flu pandemic 'unfolding in slow motion'

CORRECTED-ANALYSIS-Scientists wary of bird flu pandemic 'unfolding in slow motion' Corrects Wendy Barclay's affiliation in last paragraph By Julie Steenhuysen and Jennifer Rigby CHICAGO/LONDON, July 1 (Reuters) - Scientists tracking the spread of bird flu are increasingly concerned that gaps in surveillance may keep them several steps behind a new pandemic, according to Reuters interviews with more than a dozen leading disease experts.
G
S
Reuters - 6 days ago

Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says

Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says FRANKFURT, July 1 (Reuters) - French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
S
Reuters - 1 week ago

Verona prices lung disease therapy above expectations at $2,950/month

UPDATE 3-Verona prices lung disease therapy above expectations at $2,950/month Adds company comment in paragraph 6 By Pratik Jain June 27 (Reuters) - Verona Pharma VRNA.O said on Thursday its therapy for a chronic and potentially fatal lung disease will have a wholesale price of $2,950 per month, above the estimated cost-effectiveness range by a drug-pricing watchdog.
R
S
Reuters - 1 week ago

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

German vaccine panel endorses Astra-Sanofi's RSV shot for infants FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca AZN.L and Sanofi's SASY.PA antibody therapy to protect them against the common respiratory infection RSV. The recommendation regardless of risk factors is another boost for the product, which has seen strong U.S.
A
S
Reuters - 1 week ago

Vigil Neuroscience Announces $40 Million Strategic Investment From Sanofi

BRIEF-Vigil Neuroscience Announces $40 Million Strategic Investment From Sanofi June 27 (Reuters) - Vigil Neuroscience Inc VIGL.O : VIGIL NEUROSCIENCE ANNOUNCES $40 MILLION STRATEGIC INVESTMENT FROM SANOFI VIGIL NEUROSCIENCE INC - COMPANY EXPECTS PROCEEDS TO EXTEND CASH RUNWAY INTO 2026 VIGIL NEUROSCIENCE INC - $40 MILLION STRATEGIC INVESTMENT IN C
S
Reuters - 1 week ago

US FDA approves Verona Pharma's inhaled COPD therapy

UPDATE 2-US FDA approves Verona Pharma's inhaled COPD therapy Adds shares, adds analyst comment in paragraphs 9 and 10, management comment in paragraph 11 By Pratik Jain and Sruthi Narasimha Chari June 26 (Reuters) - The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
R
S
Reuters - 1 week ago

FDA approves Verona Pharma's therapy for 'smoker's lungs'

FDA approves Verona Pharma's therapy for 'smoker's lungs' June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. Reporting by Pratik Jain and Sruthi Narasimha Chari in Bengaluru; Edi
R
S
Reuters - 1 week ago

Sanofi-backed Formation Bio raises $372 million in late-stage funding round

Sanofi-backed Formation Bio raises $372 million in late-stage funding round June 26 (Reuters) - AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi SASY.PA . The funding was led by venture capital firm Andreessen Horowitz, Sequoia and FPV Ventures among others.
S
Reuters - 2 weeks ago

Sanofi: Riliprubart One-Year Follow-Up From Phase 2

BRIEF-Sanofi: Riliprubart One-Year Follow-Up From Phase 2 June 26 (Reuters) - Sanofi SA SASY.PA : ANNOUNCED ON TUESDAY RILIPRUBART ONE-YEAR FOLLOW-UP FROM PHASE 2 STUDY WHICH IT SAID UNDERPINNED POTENTIAL AS FIRST-IN-CLASS TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) FIRST PHASE 2 STUDY TO EVALUATE THREE SEPARATE PARTICIPAN
S
Reuters - 2 weeks ago

US CDC alerts healthcare providers of increase in dengue cases

UPDATE 1-US CDC alerts healthcare providers of increase in dengue cases Adds details in paragraphs 3,4, background throughout June 25 (Reuters) - The U.S. Centers for Disease Control and Prevention issued an advisory on Tuesday alerting healthcare providers about an increased risk of dengue virus infections in the United States. Cases of the mosquito-borne viral illness have touched a record high in the Americas this year, the agency said, echoing a similar statement from the World Health Organi
S
Reuters - 2 weeks ago

EvolutionaryScale lands $142 mln to advance AI in biology

EvolutionaryScale lands $142 mln to advance AI in biology By Anna Tong and Krystal Hu June 25 - EvolutionaryScale, an artificial intelligence startup focused on biology, said Tuesday it had raised $142 million in seed funding, led by Nat Friedman, Daniel Gross and Lux Capital. Amazon AMZN.O Web Services (AWS) and the venture capital arm of NVIDIA NVDA.O also participated in the fund raising.
A
M
N
S
Reuters - 2 weeks ago

Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital

Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital June 20 (Reuters) - Cybersecurity software firm Semperis said on Thursday it has raised $125 million in financing from J.P. Morgan and Hercules Capital, which would fund research and development at the company and help expand its global footprint. The financing comes two years after Semperis raised $200 million in a Series C round led by private equity firm KKR KKR.N .
J
S
Reuters - 2 weeks ago

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

Industry groups back drugmakers' appeal in Zantac cancer lawsuits By Brendan Pierson June 20 (Reuters) - A bid by GSK GSK.L and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.
G
P
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.